[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical practice guideline for radiation therapy in small cell lung cancer (2020 version)
Radiation Oncology Branch of Chinese Medical Association, Radiation Oncologist Branch of Chinese Medical Doctor Association Professional Committee on Radiation Oncology, China Anti-Cancer Association Experts Committee on Radiation Oncology, Radiation Oncologist Branch of Chinese Society of Clinical Oncology
Abstract Small cell lung cancer (SCLC) is one of the most common malignancies that seriously threaten the lives of patients. In order to give full play to the important role of radiotherapy in the comprehensive treatment of SCLC and bring survival benefits to patients, Chinese Society for Radiation Oncology, Radiation Oncologist Branch of Chinese Medical Doctor Association Professional Committee on Radiation Oncology, China Anti-Cancer Association and Experts Committee on Radiation Oncology, Chinese Society of Clinical Oncology formulated the clinical practice guidelines for radiotherapy of small cell lung cancer in China (2020) on the basis of the existing clinical evidence combined with experts’ opinions, which mainly include the overview, diagnosis, radiotherapy and comprehensive treatment principles of different stages of SCLC and radiotherapy,techniquesaiming to provide evidence-based guidelines for clinicians and patients in China and guide clinical practice.
Corresponding Authors:
Chen Ming, Department of Radiation Therapy, Cancer Hospital of the University of Chinese Academy of Science (Zhejiang Cancer Hospital), Hangzhou 310022,China;Email:chenming@zjcc.org.cn;Wang Lyuhua, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China;Email:wlhwq@yahoo.com
Cite this article:
Radiation Oncology Branch of Chinese Medical Association,Radiation Oncologist Branch of Chinese Medical Doctor Association Professional Committee on Radiation Oncology,China Anti-Cancer Association Experts Committee on Radiation Oncology et al. Clinical practice guideline for radiation therapy in small cell lung cancer (2020 version)[J]. Chinese Journal of Radiation Oncology, 2020, 29(8): 608-614.
Radiation Oncology Branch of Chinese Medical Association,Radiation Oncologist Branch of Chinese Medical Doctor Association Professional Committee on Radiation Oncology,China Anti-Cancer Association Experts Committee on Radiation Oncology et al. Clinical practice guideline for radiation therapy in small cell lung cancer (2020 version)[J]. Chinese Journal of Radiation Oncology, 2020, 29(8): 608-614.
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[3] Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol, 2006, 24(28):4539-4544. DOI:10.1200/JCO.2005.04.4859.
[4] Cuffe S, Moua T, Summerfield R, et al. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers[J]. J Thorac Oncol, 2011, 6(4):818-822. DOI:10.1097/JTO.0b013e31820c2f2e.
[5] Kondo R, Yoshida K, Kawakami S, et al. Different efficacy of CT screening for lung cancer according to histological type:analysis of Japanese-smoker cases detected using a low-dose CT screen[J]. Lung Cancer, 2011, 74(3):433-440. DOI:10.1016/j.lungcan.2011.05.007.
[6] van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer[J]. Lancet, 2011, 378(9804):1741-1755. DOI:10.1016/S0140-6736(11)60165-7.
[7] 孔月, 徐裕金, 唐华容, 等. 低钠血症与SCLC患者预后关系研究[J]. 中华放射肿瘤学杂志, 2016, 25(2):126-130. DOI:10.3760/cma.j.issn.1004-4221.2016.02.009.
Kong Y, Xu YJ, Tang HR, et al. Association between hyponatremia and prognosis of patients with small cell lung cancer[J]. Chine J Radiat Oncol, 2016, 25(2):126-130. DOI:10.3760/cma.j.issn.1004-4221.2016.02.009.
[8] Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors of the lung:an evidence-based proposal[J]. Endocr Relat Cancer, 2014, 21(1):1-16. DOI:10.1530/ERC-13-0246.
[9] Pelosi G, Rindi G, Travis WD, et al. Ki-67 antigen in lung neuroendocrine tumors:unraveling a role in clinical practice[J]. J Thorac Oncol, 2014, 9(3):273-284. DOI:10.1097/JTO.0000000000000092.
[10] Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC:implications for therapy[J]. Nat Rev Clin Oncol, 2017, 14(9):549-561. DOI:10.1038/nrclinonc.2017.71.
[11] van Overhagen H, Brakel K, Heijenbrok MW, et al. Metastases in supraclavicular lymph nodes in lung cancer:assessment with palpation, US, and CT[J]. Radiology, 2004, 232(1):75-80. DOI:10.1148/radiol.2321030663.
[12] Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer[J]. Mol Imaging Biol, 2010, 12(4):443-451. DOI:10.1007/s11307-009-0295-z.
[13] van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields:a planning study[J]. Radiother Oncol, 2008, 87(1):49-54. DOI:10.1016/j.radonc.2008.02.019.
[14] Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET-CT in initial staging of small-cell lung cancer:comparison with CT, bone scintigraphy and bone marrow analysis[J]. Ann Oncol, 2007, 18(2):338-345. DOI:10.1093/annonc/mdl374.
[15] Vinjamuri M, Craig M, Campbell-Fontaine A, et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer?[J]. Clin Lung Cancer, 2008, 9(1):30-34. DOI:10.3816/CLC.2008.n.005.
[16] van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of (18) FDG-PET scans in limited-disease small-cell lung cancer:a prospective study[J]. Int J Radiat Oncol Biol Phys, 2010, 77(2):329-336. DOI:10.1016/j.ijrobp.2009.04.075.
[17] Zelen M. Keynote address on biostatistics and data retrieval[J]. Cancer Chemother Rep (part 3), 1973, 4(2):31-42.
[18] Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer:veterans administration lung study group versus international association for the study of lung cancer—what limits limited disease?[J]. Lung Cancer, 2002, 37(3):271-276. DOI:10.1016/s0169-5002(02)00072-7.
[19] Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy[J]. Chest, 1994, 106(6 Suppl):320S-323S. DOI:10.1378/chest.106.6_supplement.320s.
[20] Weksler B, Nason KS, Shende M, et al. Surgical resection should be considered for stage Ⅰ and Ⅱ small cell carcinoma of the lung[J]. Ann Thorac Surg, 2012, 94(3):889-893. DOI:10.1016/j.athoracsur.2012.01.015.
[21] Verma V, Simone CB 2nd, Allen PK, et al. Multi-institutional experience of stereotactic ablative radiation therapy for stage i small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 97(2):362-371. DOI:10.1016/j.ijrobp.2016.10.041.
[22] Shioyama Y, Onishi H, Takayama K, et al. Clinical outcomes of stereotactic body radiotherapy for patients with stage Ⅰ small-cell lung cancer:analysis of a subset of the japanese radiological society multi-institutional SBRT study group database[J]. Technol Cancer Res Treat, 2018,17(1):1533033818783904. DOI:10.1177/1533033818783904.
[23] Yang CJ, Chan DY, Shah SA, et al. Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer[J]. Ann Surg, 2018, 268(6):1105-1112. DOI:10.1097/SLA.0000000000002287.
[24] Verma V, Simone CB 2nd, Allen PK, et al. Outcomes of stereotactic body radiotherapy for T1-T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation:a multicenter analysis[J]. Clin Lung Cancer, 2017, 18(6):675-681. DOI:10.1016/j.cllc.2017.03.009.
[25] Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer[J]. J Clin Oncol, 2016, 34(10):1057-1064. DOI:10.1200/JCO.2015.63.8171.
[26] Salem A, Mistry H, Hatton M, et al. Association of chemoradiotherapy with outcomes among patients with stage Ⅰ to Ⅱ vs. Stage Ⅲ small cell lung cancer:secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2019, 5(3):e185335. DOI:10.1001/jamaoncol.2018.5335.
[27] Verma V, Hasan S, Wegner RE, et al. Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage Ⅰ small cell lung cancer[J]. Radiother Oncol, 2019, 131:145-149. DOI:10.1016/j.radonc.2018.12.006.
[28] Zhu H, Guo H, Shi F, et al. Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage Ⅰ disease[J]. Lung Cancer, 2014, 86(3):334-338. DOI:10.1016/j.lungcan.2014.09.019.
[29] Chen MY, Hu X, Xu YJ, et al. The impact of prophylactic cranial irradiation for post-operative patients with limited stage small cell lung cancer[J]. Medicine (Baltimore), 2018, 97(44):e13029. DOI:10.1097/MD.0000000000013029.
[30] Yang Y, Zhang D, Zhou X, et al. Prophylactic cranial irradiation in resected small cell lung cancer:a systematic review with meta-analysis[J]. J Cancer, 2018, 9(2):433-439. DOI:10.7150/jca.21465. eCollection 2018.
[31] Xu J, Yang H, Fu X, et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer[J]. J Thorac Oncol, 2017, 12(2):347-353. DOI:10.1016/j.jtho.2016.09.133.
[32] Liu WS, Zhao LJ, Wang S, et al. Benefits of postoperative radiotherapy in multimodality treatment of resected small-cell lung cancer with lymph node metastasis[J]. Eur J Surg Oncol, 2014, 40(9):1156-1162. DOI:10.1016/j.ejso.2014.02.232.
[33] 王鹏,刘维帅,徐利明,等. 老年局限期小细胞肺癌应慎用同期放化疗[J]. 中华放射肿瘤学杂志, 2015, 24(3):237-240. DOI:10.3760/cma.j.issn.1004-4221.2015.03.003.
Wang P, Liu WS, Xu LM, et al. Concurrent chemoradiotherapy should be used with caution in elderly patients[J]. Chin J Radiat Oncol, 2015, 24(3):237-240. DOI:10.3760/cma.j.issn.1004-4221.2015.03.003.
[34] Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label, phase 3, randomized, superiority trial[J]. Lancet Oncol, 2017, 18(8):1116-1125. DOI:10.1016/S1470-2045(17)30318-2.
[35] Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202):a randomized phase 3 study[J]. Lancet Oncol, 2014, 15(1):106-113. DOI:10.1016/S1470-2045(13)70511-4.
[36] Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group[J]. N Engl J Med, 1999, 341(7):476-484. DOI:10.1056/NEJM199908123410703.
[37] De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer[J]. J Clin Oncol, 2006, 24(7):1057-1063. DOI:10.1200/JCO.2005.02.9793.
[38] Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, et al. Timing of chest radiotherapy in patients with limited stage small cell lung cancer:a systematic review and meta-analysis of randomised controlled trials[J]. Cancer Treat Rev, 2007, 33(5):461-473. DOI:10.1016/j.ctrv.2007.03.002.
[39] De Ruysscher D, Lueza B, Le Péchoux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J]. Ann Oncol, 2016, 27(10):1818-1828. DOI:10.1093/annonc/mdw263.
[40] Sun JM, Ahn YC, Choi EK, et al. Phase Ⅲ trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer[J]. Ann Oncol, 2013, 24(8):2088-2092. DOI:10.1093/annonc/mdt140.
[41] Hu X, Xia B, Bao Y, et al. Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer:a parallel comparison of two prospective studies[J]. Strahlenther Onkol, 2020, 196(2):172-181. DOI:10.1007/s00066-019-01539-1.
[42] Wang P, Liu W, Zhao L, et al. Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited-stage small-cell lung cancer?[J]. Thorac Cancer, 2015, 6(5):605-612. DOI:10.1111/1759-7714.12229.
[43] Hu X, Bao Y, Zhang L, et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer:interim analysis of a prospective randomized noninferiority trial[J]. Cancer, 2012, 118(1):278-287. DOI:10.1002/cncr.26119.
[44] Xia B, Chen GY, Cai XW, et al. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer?[J]. Radiother Oncol, 2012, 102(2):258-262. DOI:10.1016/j.radonc.2011.10.003.
[45] Hu X, Bao Y, Xu YJ, et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses[J]. Cancer, 2020, 126(4):840-849. DOI:10.1002/cncr.32586.
[46] Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340(4):265-271. DOI:10.1056/NEJM199901283400403.
[47] Salama JK, Hodgson L, Pang H, et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy (CALGB 30904)[J]. J Thorac Oncol, 2013, 8(8):1043-1049. DOI:10.1097/JTO.0b013e318293d8a4
[48] Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01):a randomised clinical trial[J]. Lancet Oncol, 2009, 10(5):467-474. DOI:10.1016/S1470-2045(09)70101-9.
[49] Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase Ⅱ randomized trial Radiation Therapy Oncology Group (RTOG) 0212:impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1):77-84. DOI:10.1016/j.ijrobp.2010.05.013.
[50] Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933):a phase Ⅱ multi-institutional trial[J]. J Clin Oncol, 2014, 32(34):3810-3816. DOI:10.1200/JCO.2014.57.2909.
[51] 董昕, 周宗玫, 刘璇, 等. 小细胞肺癌全脑预防照射海马回区保护的Ⅱ期临床研究[J]. 中华放射肿瘤学杂志, 2018, 27(7):638-642. DOI:10.3760/cma.j.issn.1004-4221.2018.07.003.
Dong X, Zhou ZM, Liu X, et al. Phase Ⅱ clinical trial of hippocampal-sparing prophylactic cranial irradiation in patients with small cell lung cancer[J]. Chin J Radiat Oncol, 2018, 27(7):638-642. DOI:10.3760/cma.j.issn.1004-4221.2018.07.003.
[52] Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229. DOI:10.1056/NEJMoa1809064.
[53] Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212):1929-1939. DOI:10.1016/S0140-6736(19)32222-6.
[54] Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer:a randomized study[J]. J. Clin. Oncol, 1999, 17(7):2092-2099. DOI:10.1200/JCO.1999.17.7.2092.
[55] Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J]. Cancer, 2011, 117(23):5423-5431. DOI:10.1002/cncr.26206.
[56] Slotman BJ, Van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a Phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962):36-42. DOI:10.1016/S0140-6736(14)61085-0.
[57] Li MX, Zhao LJ, Simone CB 2nd, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer[J]. Radiother Oncol, 2017, 125(2):331-337. DOI:10.1016/j.radonc.2017.10.005.
[58] 张文珏, 周宗玫, 陈东福, 等. 广泛期SCLC化疗后IMRT的疗效分析[J]. 中华放射肿瘤学杂志, 2016, 25(1):14-17. DOI:10.3760/cma.j.issn.1004-4221.2016.01.004.
Zhang WJ, Zhou ZM, Chen DF, et al. Clinical outcomes of extensive stage small cell lung cancer patients treated with intensive modified radiotherapy[J]. Chin J Radiat Oncol, 2016, 25(1):14-17. DOI:10.3760/cma.j.issn.1004-4221.2016.01.004.
[59] Deng L, Zhou Z, Xiao Z, et al. Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer:A propensity score-matched analysis[J]. Thorac Cancer, 2019, 10(4):799-806. DOI:10.1111/1759-7714.13001.
[60] 许昆鹏, 徐利明, 罗婧, 等. 广泛期小细胞肺癌胸部放疗最佳剂量探析[J]. 中华放射肿瘤学杂志, 2019, 28(3):180-184. DOI:10.3760/cma.j.issn.1004-4221.2019.03.004.
Xu KP, Xu LM, Luo J, et al. Analysis of optimal dose of thoracic radiotherapy for patients with extensive stage small cell lung cancer[J]. Chin J Radiat Oncol, 2019, 28(3):180-184. DOI:10.3760/cma.j.issn.1004-4221.2019.03.004.
[61] 罗婧, 徐利明, 赵路军, 等. 322例广泛期SCLC不同转移部位的生存分析[J]. 中华放射肿瘤学杂志, 2017, 26(1):17-21. DOI:10.3760/cma.j.issn.1004-4221.2017.01.004.
Luo J, Xu LM, Zhao LJ, et al. The survival analysis of different metastasis sites for 332 patients of extensive stage small cell lung cancer[J]. Chin J Radiat Oncol, 2017, 26(1):17-21. DOI:10.3760/cma.j.issn.1004-4221.2017.01.004.
[62] Zhang H, Deng L, Wang X, et al. Metastatic location of extensive stage small-cell lung cancer:implications for thoracic radiation[J]. J Cancer Res Clin Oncol, 2019, 145(10):2605-2612. DOI:10.1007/s00432-019-03000-3.
[63] Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer[J]. N Engl J Med, 2007, 357(7):664-672. DOI:10.1056/NEJMoa071780.
[64] Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer:a multicentre, randomised, open-label, Phase Ⅲ trial[J]. Lancet Oncol, 2017, 18(5):663-671. DOI:10.1016/S1470-2045(17)30230-9.
[65] Sun H, Xu L, Wang Y, et al. Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer[J]. Radiat Oncol, 2018, 13(1):250. DOI:10.1186/s13014-018-1198-4.
[66] Ni M, Jiang A, Liu W, et al. Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients:a multi-center study[J]. Radiat Oncol, 2020, 15(1):70. DOI:10.1186/s13014-020-01509-3.
[67] Harris S, Chan MD, Lovato JF, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 83(1):e53-59. DOI:10.1016/j.ijrobp.2011.11.059.
[68] 李祥攀, 肖建平, 陈秀军, 等. 小细胞肺癌脑转移全脑放疗失败后挽救性分次立体定向放疗疗效分析[J]. 中华放射肿瘤学杂志, 2012, 21(1):20-22. DOI:10.3760/cma.j.issn.1004-4221.2012.01.007.
Li XP, Xiao JP, Chen XJ, et al. Fractionated stereotactic radiotherapy for recurrent small cell lung cancer brain metastases after whole brain radiotherapy[J]. Chin J Radiat Oncol, 2012, 21(1):20-22. DOI:10.3760/cma.j.issn.1004-4221.2012.01.007.
[1]
Radiation Oncology Branch of Chinese Medical Association, Radiation Oncologist Branch of Chinese Medical Doctor Association Professional Committee on Radiation Oncology, China AntiCancer Association Experts Committee on Radiation Oncology, Radiation Oncologist Branch of Chinese Society of Clinical Oncology. Clinical practice guideline for radiation therapy of non-small cell lung cancer (2020 version)[J]. Chinese Journal of Radiation Oncology, 2020, 29(8): 599-607.
2020, Vol. 29 
